



Supplementary Fig. 3. Oxidative stress, DNA oxidation and DSB levels in the

BMs and spleens at the endpoint. (A-F) Expression of mutated *Kras* in

hematopoietic cells was induced in double ($M-Kras^{G12D}$) and triple ($Nox2^{-/-}M-Kras^{G12D}$) transgenic mice by pIpC injections. Mice were treated with NMH (250 μ g/mouse; red) or NaCl (CON; blue) i.p. thrice weekly for 5 weeks. When moribund, spleen (A-C) and bone marrow (D-F) cells were collected from them $M-Kras^{G12D}$ and $Nox2^{-/-}M-Kras^{G12D}$ mice and analyzed for (A and D) DCFDA expression in CD11b⁺ cells (B and E) 8-OHdG expression and (C and F) gamma-H2AX expression in myeloid cells (for spleens: n=8 for $Kras^{WT}$, n=12 for $M-Kras^{G12D}$, n=8 for $Nox2^{-/-}Kras^{WT}$, n=7-8 for $Nox2^{-/-}M-Kras^{G12D}$; for BMs: n=4-7 for $Kras^{WT}$, n=8-12 for $M-Kras^{G12D}$, n=3 for $Nox2^{-/-}Kras^{WT}$, n=5-6 for $Nox2^{-/-}M-Kras^{G12D}$). Student's *t*-test.

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.